Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mariaelena Capone

Showing results (51-60 of 65) with videos related to

Pageof 7
Sort By:
Journal for Immunotherapy of Cancer|July 9, 2025
Gene-expression signature predicts autoimmune toxicity in metastatic melanomaDomenico Mallardo, Mario Fordellone, Michael Bailey, et al.
Oncoimmunology|March 28, 2017
IL-15, TIM-3 and NK cells subsets predict responsiveness to anti-CTLA-4 treatment in melanoma patientsRossana Tallerico, Costanza M Cristiani, Elina Staaf, et al.
Journal for Immunotherapy of Cancer|December 28, 2020
Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapyRoberta Turiello, Mariaelena Capone, Diana Giannarelli, et al.
Cell Reports|November 9, 2022
Targeting the MITF/APAF-1 axis as salvage therapy for MAPK inhibitors in resistant melanomaPietro Carotenuto, Alessia Romano, Anna Barbato, et al.
Cancer Immunology Research|April 4, 2019
Accumulation of Circulating CCR7<sup>+</sup> Natural Killer Cells Marks Melanoma Evolution and Reveals a CCL19-Dependent Metastatic PathwayCostanza Maria Cristiani, Alice Turdo, Valeria Ventura, et al.
Biology|August 27, 2021
Clinical Outcome Prediction in COVID-19 Patients by Lymphocyte Subsets Analysis and Monocytes' iTNF-α ExpressionGabriele Madonna, Silvia Sale, Mariaelena Capone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 21, 2016
Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with IpilimumabAlexander Martens, Kilian Wistuba-Hamprecht, Marnix Geukes Foppen, et al.
Cancer Immunology, Immunotherapy : CII|October 13, 2018
Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup studyMaria Pia Pistillo, Vincenzo Fontana, Anna Morabito, et al.
Frontiers in Immunology|March 14, 2018
Corrigendum: Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup StudyPaola Queirolo, Beatrice Dozin, Anna Morabito, et al.
Frontiers in Immunology|April 28, 2017
Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup StudyPaola Queirolo, Beatrice Dozin, Anna Morabito, et al.
Pageof 7

Showing results (51-60 of 65) with videos related to

Sort By:
Pageof 7
Journal for Immunotherapy of Cancer|July 9, 2025
Gene-expression signature predicts autoimmune toxicity in metastatic melanomaDomenico Mallardo, Mario Fordellone, Michael Bailey, et al.
Oncoimmunology|March 28, 2017
IL-15, TIM-3 and NK cells subsets predict responsiveness to anti-CTLA-4 treatment in melanoma patientsRossana Tallerico, Costanza M Cristiani, Elina Staaf, et al.
Journal for Immunotherapy of Cancer|December 28, 2020
Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapyRoberta Turiello, Mariaelena Capone, Diana Giannarelli, et al.
Cell Reports|November 9, 2022
Targeting the MITF/APAF-1 axis as salvage therapy for MAPK inhibitors in resistant melanomaPietro Carotenuto, Alessia Romano, Anna Barbato, et al.
Cancer Immunology Research|April 4, 2019
Accumulation of Circulating CCR7<sup>+</sup> Natural Killer Cells Marks Melanoma Evolution and Reveals a CCL19-Dependent Metastatic PathwayCostanza Maria Cristiani, Alice Turdo, Valeria Ventura, et al.
Biology|August 27, 2021
Clinical Outcome Prediction in COVID-19 Patients by Lymphocyte Subsets Analysis and Monocytes' iTNF-α ExpressionGabriele Madonna, Silvia Sale, Mariaelena Capone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 21, 2016
Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with IpilimumabAlexander Martens, Kilian Wistuba-Hamprecht, Marnix Geukes Foppen, et al.
Cancer Immunology, Immunotherapy : CII|October 13, 2018
Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup studyMaria Pia Pistillo, Vincenzo Fontana, Anna Morabito, et al.
Frontiers in Immunology|March 14, 2018
Corrigendum: Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup StudyPaola Queirolo, Beatrice Dozin, Anna Morabito, et al.
Frontiers in Immunology|April 28, 2017
Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup StudyPaola Queirolo, Beatrice Dozin, Anna Morabito, et al.
Pageof 7